Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20714808 | 0.84 | KMT2A (0.46) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL10179719 | 0.83 | PSIP1 (0.46) | KMT2AMEN1HSD11B1ALDH1A1PSIP1 | |
| SCHEMBL10181749 | 0.80 | PSIP1 (0.43) | KMT2AMEN1HSD11B1ALDH1A1PSIP1 | |
| SCHEMBL16019344 | 0.80 | PSIP1 (0.43) | KMT2AMEN1HSD11B1ALDH1A1PSIP1 | |
| SCHEMBL696558 | 0.79 | MEN1 (0.49) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL8763365 | 0.79 | MEN1 (0.49) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL1148926 | 0.79 | MEN1 (0.49) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL515098 | 0.79 | KMT2A (0.56) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL29874131 | 0.79 | MEN1 (0.60) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL3625928 | 0.79 | MEN1 (0.60) | KMT2AMEN1HSD11B1SLC22A12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016172631-A2 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-10-27 | — | — | WO | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | KMT2A 1961/4885MEN1 4135/4885HSD11B1 3320/4885 |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KMT2A 1133/4885MEN1 1452/4885HSD11B1 2445/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | KMT2A 1656/4885MEN1 4630/4885HSD11B1 1208/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KMT2A 1133/4885MEN1 1452/4885HSD11B1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.